Vascepa's Heart Benefits
Vascepa (icosapent ethyl) reduces cardiovascular events in high-risk patients with elevated triglycerides despite statin therapy. The REDUCE-IT trial showed a 25% relative risk reduction in major events like cardiovascular death, stroke, and heart attack.[1]
How Aspirin Affects These Benefits
Patients on aspirin (typically 81-325 mg daily for secondary prevention) see amplified benefits from Vascepa. In REDUCE-IT subgroup analysis, those also taking aspirin had a 29% relative risk reduction in the primary endpoint versus 19% in non-aspirin users (interaction p=0.11, not statistically significant).[2] Aspirin use correlated with higher baseline risk, potentially explaining stronger absolute benefits (5.3% vs. 3.0% event reduction).
Why the Interaction Occurs
Aspirin inhibits platelet aggregation via COX-1 blockade, complementing Vascepa's triglyceride-lowering and anti-inflammatory effects on vascular endothelium. Combined, they target multiple atherosclerosis pathways: aspirin reduces thrombosis risk, while Vascepa stabilizes plaques and cuts inflammation.[3] No adverse interactions reported; aspirin did not increase bleeding with Vascepa.
Clinical Trial Data on Aspirin Subgroup
| Group | Primary Endpoint Reduction (HR, 95% CI) | Absolute Risk Reduction |
|-------|-----------------------------------------|--------------------------|
| All patients | 0.75 (0.68-0.83) | 4.8% |
| + Aspirin (53% of cohort) | 0.71 (0.62-0.81) | 5.3% |
| No aspirin | 0.81 (0.67-0.98) | 3.0% |
Data from REDUCE-IT; benefits consistent across doses.[2]
Implications for Patients
High-risk patients on aspirin (e.g., post-heart attack) gain more from adding Vascepa than those not on it. Guidelines like AHA/ACC endorse Vascepa for such cases without restricting aspirin co-use.4 Monitor triglycerides and lipids; no dose adjustments needed.
Related Concerns: Bleeding Risk?
No increased major bleeding with Vascepa + aspirin (1.2% vs. 1.0% placebo in REDUCE-IT). Minor bleeding slightly higher but not clinically meaningful.[2]
Sources
[1]: https://www.nejm.org/doi/full/10.1056/NEJMoa1812792
[2]: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.044115
[3]: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7525541/